Literature DB >> 6499362

Prednisolone disposition in obese men.

R L Milsap, K I Plaisance, W J Jusko.   

Abstract

Obesity is accompanied by altered secretion and disposition of sex and glucocorticoid hormones, including cortisol, and also confounds parameter normalization and drug dosage selection relative to body weight. Prednisolone disposition was assessed in eight obese and four normal male subjects after a dose of 33 mg iv. Steroid concentrations were determined by HPLC. Kinetics were related to ideal body weight (IBW) and total body weight (TBW). Uncorrected steady-state volume of distribution (Vss) of total prednisolone was 20% greater in obese subjects (36.7 and 44.1 l). This effect could be described by the relationship: Vss = 0.54 IBW + 0.09(TBW-IBW), with a distribution coefficient of 0.09 reflecting limited prednisolone uptake by fat. Protein binding parameters and albumin and transcortin concentrations were similar between groups. Uncorrected total and free prednisolone clearances (Cl) were increased in obesity (11.1 and 8.3 l/hr total; 65.4 and 46.5 l/hr free). Free prednisolone Cl correlated strongly (r = 0.80) with degree of obesity expressed as TBW/IBW. In the obese, endogenous cortisol concentrations were initially higher before exogenous steroid dosing, were suppressed at an identical rate, and returned to baseline more slowly than in normal subjects. The apparent hypersensitivity of the adrenal gland offsets the increased Cl of free prednisolone in obesity, indicating that weight-proportional dosage adjustments of this steroid in obesity should reflect TBW.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6499362     DOI: 10.1038/clpt.1984.263

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

1.  Pharmacokinetics of total and unbound prednisone and prednisolone in stable kidney transplant recipients with diabetes mellitus.

Authors:  Ileana A Ionita; Ken Ogasawara; Reginald Y Gohh; Fatemeh Akhlaghi
Journal:  Ther Drug Monit       Date:  2014-08       Impact factor: 3.681

2.  Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.

Authors:  M J Lind; J M Margison; T Cerny; N Thatcher; P M Wilkinson
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  B M Frey; F J Frey
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 4.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. III. Antimetabolites, tubulin-binding agents, platinum drugs, amsacrine, L-asparaginase, interferons, steroids and other miscellaneous antitumor agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Physiologically Based Pharmacokinetic Modeling Involving Nonlinear Plasma and Tissue Binding: Application to Prednisolone and Prednisone in Rats.

Authors:  Xiaonan Li; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2020-09-03       Impact factor: 4.030

Review 6.  Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research.

Authors:  J J Reilly; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients.

Authors:  G Powis; P Reece; D L Ahmann; J N Ingle
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 8.  Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.

Authors:  P O'Connor; J Feely
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of drugs in obesity. An update.

Authors:  G Cheymol
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

Review 10.  Drug disposition in obese humans. An update.

Authors:  D R Abernethy; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.